PitchSend

Investor Presentaiton

North America Operations growth has accelerated 132 Investor presentation Full year 2022 DKK billion 3% 100 60 80 60 60 40 40 20 20 57 40 NAO 14% 21% North America Operations reported sales growth per therapy area 1% 60 60 3% 67 61 91 0 2018 2019 GLP-1 Insulin Other diabetes 2020 Obesity care 2021 2022 Rare disease Growth at CER CER: Constant exchange rate Source: Quarterly company announcement

View entire presentation